DPP4 and type 2 diabetes mellitus: In the context of personalized medicine and pharmacogenetics, the identification of high-risk DPP4 genotypes could enable more tailored therapeutic approaches for patients with type 2 diabetes mellitus, helping clinicians balance glycemic control with autoimmune disease risk.